Arcellx

Yahoo Finance • 22 hours ago

Halper Sadeh LLC is Investigating Whether ACLX, EHAB, VRE are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • yesterday

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KW, MASI, ACLX, and VRE

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story

Yahoo Finance • yesterday

Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Loop Capital upgraded Qualcomm (QCOM)... Full story

Yahoo Finance • 2 days ago

Stocks Finish Sharply Lower on Trade Uncertainty and AI-Disruption Fears

The S&P 500 Index ($SPX) (SPY) on Monday closed down -1.04%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.66%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.21%.  March E-mini S&P futures (ESH26) fell -1.02%, and M... Full story

Yahoo Finance • 2 days ago

Stock market today: Dow drops 800 points as S&P 500, Nasdaq slide on Trump tariff fears, AI 'scare trade'

US stocks retreated on Monday as investors grappled with the fallout from the Supreme Court's rebuff of President Trump's most sweeping tariffs, while AI disruption fears gripped markets once again. The Dow Jones Industrial Average (^DJI)... Full story

Yahoo Finance • 2 days ago

Stocks Retreat on US Trade Uncertainty and Fresh AI Worries

The S&P 500 Index ($SPX) (SPY) today is down -1.20%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.58%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.47%.  March E-mini S&P futures (ESH26) are down -1.23%, and March E-mini... Full story

Yahoo Finance • 2 days ago

Stocks Slip on US Trade Uncertainty

The S&P 500 Index ($SPX) (SPY) today is down -0.22%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.24%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.66%.  March E-mini S&P futures (ESH26) are down -0.25%, and March E-mini... Full story

Yahoo Finance • 2 days ago

Stocks making the biggest moves midday: KKR, Blackstone, CrowdStrike, International Paper & more

Check out the companies making the biggest moves midday: Financials – The financials sector of the S & P 500 slid more than 3% in midday trading, the worst performer in the broad market. Alternative asset managers KKR and Blackstone slid r... Full story

Yahoo Finance • 3 days ago

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges

Perceptive Advisors disclosed a sale of 1,002,282 Arcellx(NASDAQ:ACLX) shares in a February 17, 2026, SEC filing, with the estimated transaction value at $79.96 million based on quarterly average pricing. What happened According to a SEC... Full story

Yahoo Finance • 9 days ago

Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study

Arcellx Incorporated (NASDAQ:ACLX) is one of 17 biotechnology stocks with more than 50% upside. On February 12, Qize Ding from Rothschild & Co Redburn downgraded the rating on Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral. In the... Full story

Yahoo Finance • 16 days ago

Ken Fisher's Strategic Moves: iShares 7-10 Year Treasury Bond ETF Takes Center Stage

This article first appeared on GuruFocus. Exploring Ken Fisher (Trades, Portfolio)'s Latest 13F Filing and Investment Strategy Warning! GuruFocus has detected 5 Warning Signs with NVDA. Is NVDA fairly valued? Test your thesis with our fr... Full story

Yahoo Finance • 2 months ago

Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as Johnson & Johnson, Arcellx, Gilead, Bris... Full story

Yahoo Finance • 3 months ago

Assessing Arcellx (ACLX) Valuation Following Positive Pivotal CAR T Data and Commercial Launch Plans

Arcellx (ACLX) just put fresh Phase 2 iMMagine-1 data for its multiple myeloma CAR T, anitocabtagene autoleucel, on the table, and the results look clinically meaningful for both patients and shareholders. See our latest analysis for Arce... Full story

Yahoo Finance • 3 months ago

Arcellx Enters Oversold Territory (ACLX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 4 months ago

CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight

The dynamics of the CAR T-cell therapy market are anticipated to change due to the extensive R&D activities, an increase in investment for research and development of the new CAR T-cell therapy, such as zamtocabtagene autoleucel (Miltenyi... Full story

Yahoo Finance • 7 months ago

Biotech sector slips amid reported return of ousted FDA official

[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad w... Full story

Yahoo Finance • 8 months ago

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story

Yahoo Finance • 11 months ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the Col... Full story

Yahoo Finance • 2 years ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma -- -- The companies expand the scope of the... Full story

Yahoo Finance • 2 years ago

Kite and Arcellx Announce Expansion in Strategic Partnership

-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas -- -- Kite exercises option to Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma -- -- Arcellx to receive $200M equity investme... Full story